Search Results - "Alshuth, U."

Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial by Stahmeyer, J. T., Krauth, C., Bert, F., Pfeiffer-Vornkahl, H., Alshuth, U., Hüppe, D., Mauss, S., Rossol, S.

“…Summary Viral hepatitis is a major public health problem affecting millions of people worldwide. Long‐term consequences are the development of liver cirrhosis…”
Get full text

Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study by Marcellin, P, Xie, Q, Paik, S.W, Flisiak, R, Piratvisuth, T, Petersen, J, Asselah, T, Cornberg, M, Ouzan, D, Foster, G.R, Papatheodoridis, G.V, Messinger, D, Regep, L, Bakalos, G, Alshuth, U, Wedemeyer, H

Get full text

Screening for autoantibodies in chronic hepatitis C patients has no effect on treatment initiation or outcome by Mauss, S., Berger, F., Schober, A., Moog, G., Heyne, R., John, C., Pape, S., Hueppe, D., Pfeiffer-Vornkahl, H., Alshuth, U.

“…Summary Autoantibodies in hepatitis C virus–infected patients may indicate autoimmune hepatitis or other immune‐mediated diseases. This may impact safety and…”
Get full text

Add on Interferon-Alpha-2a for the Treatment of HBeAg Negative Hepatitis B Patients Receiving Effective Nucleos(t)ide Therapy: Interim Results of the Prospective Multicentre PADD-On Trial by Sprinzl, M.F, Grambihler, A, Teuber, G, Ebert, M, Zeuzem, S, Lohmeyer, J, Cornberg, M, Tacke, F, Löhr, H, Berg, T, Lammert, F, Schott, E, Heyne, R, Berg, C, Dollinger, M, Pathil-Warth, A, Geisler, F, Spengler, U, Thimme, R, Weigand, K, Alshuth, U, Ehrlich, A, Riedl, M, Kittner, J, Schuchmann, M, Galle, P.R

Get full text

Treatment results of chronic hepatitis C genotype 5 and 6 infections in Germany by Mauss, S, Berger, F, Vogel, M, Pfeiffer-Vornkahl, H, Alshuth, U, Rockstroh, J K, Niederau, C, Hüppe, D

“…Chronic hepatitis C due to HCV genotype 5 and 6 infection is infrequently reported and patients are usually not included in trials. As boceprevir and…”
Get more information

Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection by Mihm, U., Welker, M.-W., Teuber, G., Wedemeyer, H., Berg, T., Sarrazin, C., Böhm, S., Alshuth, U., Herrmann, E., Zeuzem, S.

“…Summary Ribavirin amplifies the interferon‐alpha (IFN) signalling cascade. As ribavirin needs 4 weeks to reach steady state, ribavirin priming may optimize…”
Get full text

P730 ADVERSE EVENTS AND CO-MEDICATION: A COMPARISON BETWEEN DUAL- AND TRIPLE-COMBINATION THERAPIES IN GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C by Schott, E, Schober, A, Link, R, Weber, B, Rieke, A, Moog, G, Spengler, U, Heyne, R, Jung, M.-C, Teuber, G, Frank Doss, M, Roessle, M, Mauss, S, Alshuth, U, Hueppe, D

Get full text

P1149 PHYSICIAN ADHERENCE TO AND EFFICACY OF TRIPLE THERAPY WITH TELAPREVIR (TVR) PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN (PEGIFN/RBV) IN A REAL-LIFE SETTING by Mauss, S, Schober, A, John, C, Lutz, T, Moog, G, Bruch, H.R, Teuber, G, Christensen, S, Heyne, R, Pape, S, Naumann, U, Roessle, M, Schiffelholz, W, Loehr, H, Alshuth, U, Hueppe, D

Get full text

P1147 OUTCOMES AND COSTS OF TREATING HEPATITIS C WITH PROTEASE INHIBITORS: RESULTS FROM A MULTI-CENTRE STUDY by Stahmeyer, J.T, Rossol, S, Bert, F, Abdelfattah, A.M, Mauss, S, Heyne, R, John, C, Pape, S, Schober, A, Teuber, G, Bruch, H.R, Zehnter, E, Hueppe, D, Pfeiffer-Vornkahl, H, Alshuth, U, Krauth, C

Get full text

Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, non-interventional PAN cohort by Mauss, S, Böker, K, Buggisch, P, Christensen, S, Hofmann, W P, Schott, E, Pfeiffer-Vornkahl, H, Alshuth, U, Hüppe, D

“…The efficacy and safety of peginterferon alfa-2a (PEG-IFN) plus ribavirin (RBV) and either boceprevir (BOC) or telaprevir (TVR), and physician adherence to…”
Get more information

P1146 VIROLOGICAL RESPONSE AND TOLERANCE TO BOCEPREVIR OR TELAPREVIR PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN TRIPLE THERAPY IN HIV–HCV CO-INFECTED PATIENTS: REAL-LIFE FINDINGS FROM THE PAN STUDY by Baumgarten, A, Holm, S, Lutz, T, Schranz, D, Mauss, S, Hillenbrand, H, Moll, A, Scholten, S, Schmidt, W, Goelz, J, Hintsche, B, Schleehauf, D, Fenske, S, Stephan, C, Prziwara, D, Koeppe, S, Alshuth, U, Jaeger, H

Get full text

P1148 BASELINE FACTORS ASSOCIATED WITH SUSTAINED VIROLOGIC RESPONSE (SVR) IN PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS PLUS PEGINTERFERON ALFA-2a (40KD) AND RIBAVIRIN by Christensen, S, Boeker, K.H.W, Eisenbach, C, Schuchmann, M, Lutz, T, Heyne, R, Moog, G, Mauss, S, Jung, M.-C, Teuber, G, Emke, F, Naumann, U, Frank Doss, M, Lucadou, A.v, Alshuth, U, Hueppe, D

Get full text

P1141 SUSTAINED VIROLOGICAL RESPONSE (SVR) IN HCV TREATMENT-EXPERIENCED PATIENTS AFTER TRIPLE THERAPY WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN IN A REAL-LIFE SETTING by Boeker, K.H.W, Link, R, Baumgarten, A, Stoehr, A, Heyne, R, Roessle, M, Schott, E, Ullrich, R, Erren, P, Herold, C, Schmidt, W, Simon, K.-G, Geissler, M, Schiffelholz, W, Alshuth, U, Hueppe, D, Mauss, S

Get full text

P1136 TRIPLE THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN IN A REAL-LIFE SETTING: IS IT POSSIBLE TO ACHIEVE SVR RATES COMPARABLE TO PIVOTAL TRIALS? by Buggisch, P, Schober, A, Bruch, H.R, Antoni, C, Loehr, H, Herrmann, A, Steffens, H, Moog, G, Haessner, J, Hoerster, H.-G, John, C, Schlueter, H.-J, Link, R, Heyne, R, Spengler, U, Alshuth, U, Hueppe, D

Get full text

P1150 BASELINE CHARACTERISTICS AND TREATMENT EFFICACY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2a AND RIBAVIRIN IN 253 HCV GENOTYPE 1 NONRESPONDER PATIENTS IN A REAL-WORLD SETTING by Hofmann, W.P, Mauss, S, Baumgarten, A, Boeker, K.H.W, Link, R, Naumann, U, Geyer, P.R, Schuchmann, M, Stoehr, A, Loehr, H, Schober, A, Moog, G, Holm, S, Heyne, R, Eisenbach, C, Lutz, T, Alshuth, U, Hueppe, D

Get full text

Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial by Witthöft, Th, Möller, B., Wiedmann, K. H., Mauss, St, Link, R., Lohmeyer, J., Lafrenz, M., Gelbmann, C. M., Hüppe, D., Niederau, C., Alshuth, U.

“…The combination treatment of peginterferon alpha‐2a (PEG‐IFN alpha‐2a; Pegasys®) plus ribavirin (RBV) is recommended as a standard care for HCV infections…”
Get full text

918 VIROLOGICAL EFFICACY OF BOCEPREVIR (BOC) AND TELAPREVIR (TVR) PLUS PEGINTERFERON alfa-2a (P)/ RIBAVIRIN (R) UNTIL WEEK 12 IN DRUG ADDICTED PATIENTS WITH GT-1 INFECTION: FIRST REAL LIFE REPORT by Weber, B, Ablasmaier-Stuetzel, B, Naumann, U, Schleehauf, D, Bachner, C, Goelz, J, Bannout, F, Isernhagen, K, Gottberg, J, Forestier, N, Buescher, K.-G, Baumgarten, A, Backmund, M, Alshuth, U, Walcher, S

Get full text

805 WEEK 4 AND 12 EFFICACY OF TELAPREVIR (TVR) IN COMBINATION WITH PEGINTERFERON alfa 2a/RIBAVIRIN (P/R) IN TREATMENT EXPERIENCED PATIENTS WITH GT-1 UNDER REAL LIFE CONDITIONS by Christensen, S, Mauss, S, Eisenbach, C, Jung, M.-C, Roessle, M, Emke, F, Pape, S, Lucadou, A.v, Frank Doss, M, Schuchmann, M, Ullrich, R, Erren, P, Alshuth, U, Hueppe, D, Buggisch, P

Get full text

875 REAL-WORLD EFFICACY AND SAFETY OF BOCEPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY by Moog, G, Schober, A, Antoni, C, Bruch, H.R, Herrmann, A, John, C, Steffens, H, Leuschner, M, Spengler, U, Moeller, B, Isernhagen, K, Hueppe, D, Alshuth, U, Mauss, S

Get full text

830 CHOLESTEROL LEVELS AND PRESENCE OF DIABETES PREDICT EARLY VIROLOGICAL RESPONSE TO TRIPLE THERAPY WITH TELAPREVIR, PEG-INTERFERON alfa-2a 180 μg AND RIBAVIRIN IN CHRONIC HEPATITIS C by Jaeckel, E, Zehnter, E, John, C, Heyne, R, Teuber, G, Schiffelholz, W, Christensen, S, Antoni, C, Pape, S, Roessle, M, Loehr, H, Stoll, S, Alshuth, U, Hueppe, D, Mauss, S, Manns, M.P

Get full text